For example, apitolisib (GDC-0980, Genentech, South San Francisco, CA), a potent inhibitor of class I PI3K and mTOR kinase (TORC1/2), has shown significant activity in vitro and in vivo against biologically aggressive endometrial tumors harboring PI3K driver mutations (English et al., 2013). Here, PIK3CA is linked to endometrium neoplasm.